Novo Nordisk to Invest ~$117.4M in Expansion of its Production Facilities in Denmark
Shots:
- Novo Nordisk to invest $117.4M in upgrading and expanding facilities at its production site in Kalundborg- Denmark
- The facilities currently develop diabetic therapies and will be rebuilt and expanded for the future production of these and the next generation of diabetic therapies. The projects are expected to be completed in 2022
- The investment in production facilities will strengthen its presence in Denmark and Kalundborg
Click here to read full press release/ article | Ref: Novo Nordisk | Image: New Age
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com